Limo Chen | Editor
Affilation: Baylor College of Medicine, USA
After I finished my postdoctoral training at Baylor College of Medicine (Immunology) and Harvard Medical School (Translational Cancer Research), I joined the Department of Immunology at MD Anderson focusing on tumor immunology. In 2014, I was recruited to the Division of Cancer Medicine at MD Anderson Cancer Center as a junior faculty, leading the preclinical study of mechanisms of resistance to anti-PD-1/PD-L1 immunotherapy for cancer. Through MD Anderson Cancer Moon Shot Program, my discovery led to the clinical trial of combination immunotherapy of CD38 and PD-1/PD-L1 blockade for cancer patients. Thereby, I was granted Career Development Award (2015) and Career Enhancement Award (2017) from NCI SPORE program, as well as Conquer Cancer Foundation of ASCO Merit Award (2017).
My research interests include the resistance mechanisms of immune checkpoint inhibitors (e.g., anti-PD-1, anti-PD-L1, anti-CTLA-4) for cancer therapy, tumor microenvironment, interaction between tumor cells and immune cells, mutual regulation of EMT and immunosuppression.